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Hemolytic uremic syndrome (HUS) is a disorder characterized by the presence of the 
classic triad: microangiopathic hemolytic anemia, thrombocytopenia and acute renal 
injury. HUS without acute renal failure can be confused with other hematologic diseases. 
An infantile HUS caused by a Shiga-toxin-producing Escherichia coli (STEC) O145 strain 
carrying genotype stx2, ehxA, eae subtype β1 is herein reported. The infant did not 
require dialysis during the acute stage of HUS, evolved favorably, maintained normal 
blood pressure and normal renal function and had no recurrence until the last control. 
This could be due to several factors, such as the characteristics of infecting STEC strain 
and a reduction in host susceptibility to renal injury. This report highlights the regional 
participation of non-O157 STEC in childhood diseases and the importance of performing 
active surveillance for all forms of HUS. 
© 2014 Asociación Argentina de Microbiología. Published by Elsevier España, S.L. All 
rights reserved.
Síndrome urémico hemolítico con compromiso renal leve debido a una cepa 
de Escherichia coli productora de toxina Shiga [Shiga-toxin-producing Escherichia 
coli (STEC)] O145
Resumen
El síndrome urémico hemolítico (SUH) es una afección caracterizada por la presencia 
de la tríada clásica: anemia hemolítica microangiopática, trombocitopenia y compro-
miso renal agudo. Los casos de SUH sin insufi ciencia renal pueden confundirse con otras 
enfermedades hematológicas. Presentamos un caso de SUH pediátrico causado por una 
cepa de Escherichia coli productora de toxina Shiga [Shiga-toxin-producing Escherichia 
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Hemolytic uremic syndrome (HUS) is a disorder characteri-
zed by the presence of the classic triad: microangiopathic 
hemolytic anemia, thrombocytopenia, and acute renal in-
jury8,10. There are 2 forms of HUS: typical (with diarrhea in 
the prodromal period) and atypical (without diarrhea in 
that period). In addition, HUS may be “complete” (comple-
te triad: microangiopathic hemolytic anemia, thrombocyto-
penia, and acute renal involvement) or “incomplete” (when 
the patient does not have any of the manifestations of the 
classical triad). The typical one, also known as post-enteric 
HUS or STEC-HUS is the most common, being responsible for 
90-95% of cases and occuring after intestinal infection by 
strains of Shiga-toxin-producing Escherichia coli (STEC). It 
occurs mainly in children under 5 years of age and is usually 
preceded by episodes of bloody diarrhea or hemorrhagic co-
litis. STEC-HUS is the leading cause of acute renal failure 
and the second leading cause of chronic renal failure and 
renal transplantation in children under 5 years of age10. 
Sometimes, HUS cases present thrombocytopenia and 
anemia without acute renal failure, making diagnosis diffi cult4.
We here describe a case of a child with HUS, with the aim 
of alerting healthcare professionals, especially pediatricians, 
hematologists, nephrologists and microbiologists in this 
regard, 
On January 16, 2013 a 1 year-old infant from “Las 
Piedras” (in the urban area of Canelones Department, 
Uruguay) was brought to the emergency room with vomiting 
and fever. During the preceding 48 hours, he had fever 
without diarrhea and had vomited on several occasions. On 
examination, he was febrile (38.5 ºC axillary), depressed, 
with intense mucocutaneous pallor and upper right foot 
petechiae. He was well hydrated and perfused with a heart 
rate of 150 cpm, no murmurs and PA records of 110/86 Hg 
mm. Edema was not present, and the remaining examination 
was normal. Hematological investigations revealed: RBC: 
2,200,000/μl; WBC: 24,500/μl; neutrophils: 36%; 
lymphocytes: 44%; hemoglobin: 6.6 g/dl; MCV: 75 fL; 
hematocrit: 18.7%; platelet count: 54,000/μl. Biochemical 
analysis displayed the following values: azotemia: 0.51 g/l; 
creatinine: 0.47 mg/dl (estimates of glomerular fi ltration: 
99 ml/min per 1.73 m2); serum sodium, 143 mEq/l and 
serum potassium, 4.1 mEq/l. The urine analysis contained 
20 erythrocytes per fi eld with hyaline cylinders and showed 
proteinuria, intense hemoglobinuria and ketonuria. 
The infant was admitted to a pediatric ward with a 
diagnosis of hemolytic anemia. He remained 
hemodynamically stable with tachycardia and preserved 
diuresis. He was examined by a hemato-oncologist, who 
performed a new peripheral blood count and a peripheral 
blood smear, showing: Hb 5.2 g/dl, RBC 2,000,000/μl, WBC 
22,400/μl, reticulocytes 5%, platelets 71,000/μl and 5-10 
fragmented erythrocytes (schizocytes) every 40 erythrocytes, 
respectively (Fig. 1) With these results, HUS without renal 
failure was diagnosed. 
The stool sample collected on January 17th was sent to 
the Bacteriology and Virology Department for STEC 
screening according to the previously described procedure11. 
PCR was performed on 20 suspected E. coli colonies to 
detect stx1 and stx2 genes. 
Confi rmation of isolates as E. coli was performed through 
biochemical tests and serotyping was conducted using 
commercial antisera (Statens Serum Institute, Denmark) for 
serogrouping and our own antibodies for H antigens.
The presence of sequences related to the ehxA and eae 
genes was determined by PCR7. Subtyping of the eae gene 
was also performed by PCR1. Antimicrobial susceptibility to 
amikacin, ampicillin, ceftriaxone, cefuroxime, ciprofl oxacin, 
cloramphenicol, colistin, gentamicin, nalidixic acid, 
nitrofurantoin, streptomycin, tetracycline, and trimethoprim-
sulfamethoxazole was established according to the Clinical 
Laboratory Standards Institute (CLSI) guidelines3.
The 20 colonies of E. coli analyzed corresponded to STEC 
serotype O145:HNT, with genotype: stx2, ehxA, eae subtype 
β1, which were susceptible to all tested antibiotics.
durante la etapa aguda del SUH, evolucionó favorablemente y no tuvo recurrencias hasta 
el último control; además, mantuvo cifras normales de presión arterial y función renal 
normal. Esto puede deberse a varios factores: características de la cepa STEC infectante 
y susceptibilidad del hospedero al daño renal, entre otros. Este hallazgo destaca la par-
ticipación regional de STEC no-O157 en enfermedades de la infancia y la importancia de 
realizar una vigilancia activa de todas las formas de SUH. 
© 2014 Asociación Argentina de Microbiología. Publicado por Elsevier España, S.L. Todos 
los derechos reservados.
Figure 1 Peripheral blood smear stained with the Giemsa pro-
cedure. The black arrows indicate the schizocytes.
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On January 19th, 2013 the patient was admitted to an 
intermediate care unit for monitoring. He remained 
hemodynamically stable with preserved diuresis and 
hypertension for which he received inhibitors of the 
angiotensin-converting enzyme (IACE), 1.5 mg/kg/day.
Azotemia and creatinine remained normal. On January 
20th, 2013 he received a 180 ml transfusion of concentrated 
red blood cells and antibiotic treatment with i/v 
ceftriaxone was started (100 mg/ kg/day), due to 
suspected widespread bacterial infection from the 
gastrointestinal tract. As the infant showed progressive 
improvement with normal reticulocyte count and blood 
pressure, IACE administration was discontinued. Ten days 
of i/v ceftriaxone treatment were completed. After being 
examined by the pediatrician and the nephrologist, the 
child was discharged (01/29/13) with instructions of 
monthly clinical nephrologic controls.
Until the date of the last control (06/23/13) the infant 
had no recurrence, maintained normal blood pressure and 
normal renal function. 
This is the fi rst local report of a pediatric case of STEC-
HUS caused by O145 STEC strain with hemolytic anemia and 
thrombocytopenia but without obvious acute renal failure 
(Table 1). By defi nition, all patients with HUS manifest some 
degree of renal involvement. This form of presentation 
without acute renal failure can be easily mistaken with 
other hematologic diseases4. In this case the guiding light 
was the fi nding of schizocytes in the peripheral blood 
smear. HUS is a relatively common disease in our country, 
having an estimated annual incidence of 4-5 cases per 
100,000 children under 5 years of age11. This fi gure is lower 
than that reported by Argentina, where approximately 
400 new cases are notifi ed per year, with an incidence of 
12.2/100,000 in children under 5 years of age9. Between 
2002 and 2008 we studied 36 children with a clinical 
diagnosis of “complete” post-enteric HUS; in three cases 
we recovered STEC strains belonging to serotypes O157:H7, 
O111:NM, and STEC O26:H11; in a fourth case an O26:H11/
O145:HNT STEC co-infection was detected6,11. 
In 2013, we analyzed 3 cases: the case reported here; 
another one of a 12 month-old infant with complete HUS 
from whom O26:NM STEC was recovered; and a third case of 
a two year-old infant who died in the acute phase of the 
illness and from whom it was not possible to recover STEC. 
Table 1 shows the characteristics of our recovered STEC 
strains. 
In Uruguay, HUS cases usually occur in the warmer months 
(spring, summer and early fall) in eutrophic children, from 
homes with an acceptable socioeconomic level, often living 
in small villages but not in rural areas6,11. The cases are 
usually preceded by episodes of bloody diarrhea without an 
obvious infl ammatory component, all showing values of 
azotemia, serum creatinine and glomerular fi ltration 
compatible with some degree of renal injury; most of them 
require dialysis in the acute phase. 
The infant in the present case lived in a home belonging 
to an acceptable socioeconomic level, did not have previous 
diarrhea and did not require dialysis. The outcome was 
favorable despite antimicrobial therapy that can produce 
undesired effects. This could be due to several factors: the 
characteristics of the infecting STEC strain (e.g. type and 
amount of toxin produced; absence of other unknown 
virulence factors; etc.), the infecting dose or different host 
susceptibility to renal injury.
We could not establish the food involved and neither 
were there HUS cases or diarrhea in other members of the 
family. HUS is not listed as a notifi able event in Public 
Health regulations, and since the health team and 
the offi cial health authorities do not usually perform the 
systematic epidemiological investigation of cases, most of 
them are not reported.
O145 STEC strains are part of Karmali´s seropathotype B and 
have a pathogenic potential similar to that of O157 isolates.
The fi nding we here report reinforces our suggestion in 
previous communications about the comparative regional 
importance of non-O157 STEC and O157:H7 strains in severe 
cases of disease in children under 5 years of age, and also 
stresses the importance of performing active surveillance 
for all forms of HUS (with or without diarrhea at the 
prodromal stage), including those cases that can occur 
after extra-intestinal infection by STEC2,5,6,11.
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Table 1 Characteristics of STEC strains recovered from children with HUS in Uruguay
Case Year Serotype STEC recovered Genotype Bloody diarrea prior Acute renal failure
1 2002 O157:H7 stx2, eae γ1, ehxA Yes Yes
2 2004 O111:NM stx1/2, eae γ2, ehxA Yes Yes
3a 2005 O26:H11 stx1, eae β1, ehxA Yes Yes
O145:HNT stx2, eae β1, ehxA
4 2005 O26:H11 stx1, eae β1, ehxA Yes Yes
5 2013 O145:HNT stx2, eae β1, ehxA No No
6 2013 O26:NM stx1/2, eae β1, ehxA Yes Yes
Case number 3 was coinfected with both STEC serotypes (O26:H11 and O145:HNT).
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